THE RISK OF MALIGNANCY IN THE SURGICAL MARGIN AT RADICAL PROSTATECTOMY REDUCED ALMOST 3-FOLD IN PATIENTS GIVEN NEOADJUVANT HORMONE-TREATMENT

Citation
J. Hugosson et al., THE RISK OF MALIGNANCY IN THE SURGICAL MARGIN AT RADICAL PROSTATECTOMY REDUCED ALMOST 3-FOLD IN PATIENTS GIVEN NEOADJUVANT HORMONE-TREATMENT, European urology, 29(4), 1996, pp. 413-419
Citations number
20
Categorie Soggetti
Urology & Nephrology
Journal title
ISSN journal
03022838
Volume
29
Issue
4
Year of publication
1996
Pages
413 - 419
Database
ISI
SICI code
0302-2838(1996)29:4<413:TROMIT>2.0.ZU;2-0
Abstract
Objectives: To investigate the outcome of neo-adjuvant hormone treatme nt before radical prostatectomy regarding local tumour extension, peri -operative blood loss and operation time. Patients: Of 111 surgically treated patients with prostate cancer (T1(b-)T3(a), N-0, M(0), G(1-3)) , 55 were randomised to immediate radical prostatectomy and 56 to 3 mo nths of neo-adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks to prevent fl are). Results: No differences were found in blood loss or operation ti me but patients who had neo-adjuvant treatment had a significantly low er frequency of positive margins (41 vs. 23%, p = 0.013). Conclusion: Neo-adjuvant treatment does not facilitate radical prostatectomy but m ay improve the chance of local cure. This must, however, be documented with long-term follow-up in randomised patients.